Screening of Novel Pharmacogenetic Candidates for Mercaptopurine-Induced Toxicity in Patients With Acute Lymphoblastic Leukemia
A small proportion of patients with acute lymphoblastic leukemia (ALL) may experience severe leukopenia after treating with 6-mercaptopurine (6MP), which can be largely explained by germline variants in TPMT and NUDT15. However, a minority of patients who suffered such adverse drug reaction have NUD...
Saved in:
Main Authors: | Minyuan Cao (Author), Dandan Yin (Author), Yun Qin (Author), Fei Liao (Author), Yali Su (Author), Xuyang Xia (Author), Ju Gao (Author), Yiping Zhu (Author), Wei Zhang (Author), Yang Shu (Author), Xiaoxi Lu (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2020-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
ITPA, TPMT, and NUDT15 Genetic Polymorphisms Predict 6-Mercaptopurine Toxicity in Middle Eastern Children With Acute Lymphoblastic Leukemia
by: Borhan Moradveisi, et al.
Published: (2019) -
Effects of TPMT, NUDT15, and ITPA Genetic Variants on 6-Mercaptopurine Toxicity for Pediatric Patients With Acute Lymphoblastic Leukemia in Yunnan of China
by: Xiaoyan Mao, et al.
Published: (2021) -
Genetic variants of genes involved in thiopurine metabolism pathway are associated with 6-mercaptopurine toxicity in pediatric acute lymphoblastic leukemia patients from Ethiopia
by: Awol Mekonnen Ali, et al.
Published: (2023) -
Severe recurrent nocturnal hypoglycemia during chemotherapy with 6-mercaptopurine in a child with acute lymphoblastic leukemia
by: Eun Mi Cho, et al.
Published: (2018) -
Implementation of pharmacogenetics for treatment of patients with acute lymphoblastic leukemia
by: Violeta Graiqevci-Uka, et al.
Published: (2024)